Lepu Medical Technology Co: Q3 net profit surged 176.18% year-over-year on strong pharma and medical services growth

Revenue and net profit declined slightly year-over-year, but adjusted net profit and operating cash flow grew. The company advanced its innovation pipeline, expanded internationally, and proposed a cash dividend. Risks include policy-driven price pressure and regulatory changes.

Original document: Lepu Medical Technology (Beijing) Co., Ltd. Class A [300003] Interim report — Aug. 23 2025

Shares in a number of Chinese biopharmaceutical firms closed higher on Tuesday after Beijing called on insurers to invest in the sector.

Following the announcement, shares in Staidson Beijing Biopharmaceuticals closed 15% higher, while Thalys Medical Technology surged 10% and Lepu Medical Technology soared 8% during the close of trading on Tuesday.

The National Health Security Administration will tap commercial insurers to invest in the country's biopharmaceutical sector and help develop homegrown drugs, it said Monday.

China is encouraging commercial insurers to set up investment funds to "cultivate patient capital" to foster the development of innovative drugs, the NHSA said.

Lepu Medical Technology Beijing posted first-quarter net profit attributable to shareholders of 378.6 million yuan, down 21% from 481.9 million yuan the previous year.

Earnings per share went down to 0.2053 yuan from 0.2585 yuan, according to an Saturday filing with the Shenzhen bourse.

The medical device and pharmaceuticals company's revenue declined 9.7% year over year to 1.74 billion yuan from 1.92 billion yuan.

Shares of Lepu Medical Technology Beijing closed 2% higher Monday.

Lepu Medical Technology Beijing posted 2024 net profit attributable to shareholders of 246.9 million yuan, down 80% from 1.26 billion yuan the previous year.

Earnings per share went down to 0.1336 yuan from 0.6757 yuan, according to an Saturday filing with the Shenzhen bourse.

The medical device and pharmaceuticals company's revenue declined 24% year over year to 6.10 billion yuan from 7.98 billion yuan.

Lepu Medical Technology Beijing declared a dividend of 0.135 yuan per share.

Shares of the company closed 2% higher Monday.

Lepu Medical's 2024 revenue fell 23.5% and net profit dropped 80.4% due to asset impairments and price pressures, but core cardiovascular device segments grew. The company plans to focus on innovation, cost control, and international expansion in 2025.

Original document: Lepu Medical Technology (Beijing) Co., Ltd. Class A [300003] Annual Financial Statement — Apr. 19 2025

Q1 2025 revenue declined 9.67% year-over-year, but net profit and cash flow improved sequentially. Medical devices and pharmaceuticals showed strong sequential growth, while gross margin faced policy-driven pressure.

Original document: Lepu Medical Technology (Beijing) Co., Ltd. Class A [300003] Interim report — Apr. 19 2025